Jivi® is indicated for your previously treated patients aged ≥12 years1

Study Design Chart
A clinical immune response, associated with anti-PEG antibodies, manifested as symptoms of acute hypersensitivity and/or loss of drug effect primarily in patients <6 years old (10 out of 44)1:
  • This occurred early in treatment (in the first four exposure days) and was transient
  • Patients were able to resume their previous effective FVIII therapy4
  • As of January 2018 interim analysis.3
  • FVIII, Factor VIII; PEG, polyethylene glycol.